|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM15 |
Gene summary for TRIM15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM15 | Gene ID | 89870 |
| Gene name | tripartite motif containing 15 | |
| Gene Alias | RNF93 | |
| Cytomap | 6p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0001704 | UniProtAcc | Q5SRL0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 89870 | TRIM15 | HCC1_Meng | Human | Liver | HCC | 1.24e-61 | 3.05e-01 | 0.0246 |
| 89870 | TRIM15 | HCC2_Meng | Human | Liver | HCC | 3.92e-18 | 1.71e-01 | 0.0107 |
| 89870 | TRIM15 | S027 | Human | Liver | HCC | 9.79e-15 | 1.07e+00 | 0.2446 |
| 89870 | TRIM15 | S028 | Human | Liver | HCC | 9.07e-30 | 1.23e+00 | 0.2503 |
| 89870 | TRIM15 | S029 | Human | Liver | HCC | 3.81e-30 | 1.34e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
| GO:001905822 | Liver | HCC | viral life cycle | 209/7958 | 317/18723 | 2.05e-17 | 2.09e-15 | 209 |
| GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
| GO:004440322 | Liver | HCC | biological process involved in symbiotic interaction | 183/7958 | 290/18723 | 9.13e-13 | 4.59e-11 | 183 |
| GO:005079212 | Liver | HCC | regulation of viral process | 109/7958 | 164/18723 | 4.52e-10 | 1.45e-08 | 109 |
| GO:005170122 | Liver | HCC | biological process involved in interaction with host | 128/7958 | 203/18723 | 2.51e-09 | 6.91e-08 | 128 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:0039528 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 30/7958 | 34/18723 | 3.88e-08 | 8.39e-07 | 30 |
| GO:00027533 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway | 46/7958 | 60/18723 | 7.37e-08 | 1.49e-06 | 46 |
| GO:005212612 | Liver | HCC | movement in host environment | 109/7958 | 175/18723 | 9.58e-08 | 1.89e-06 | 109 |
| GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
| GO:190390012 | Liver | HCC | regulation of viral life cycle | 94/7958 | 148/18723 | 1.93e-07 | 3.49e-06 | 94 |
| GO:00395291 | Liver | HCC | RIG-I signaling pathway | 24/7958 | 27/18723 | 7.23e-07 | 1.12e-05 | 24 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:001907611 | Liver | HCC | viral release from host cell | 28/7958 | 34/18723 | 2.21e-06 | 2.99e-05 | 28 |
| GO:003589011 | Liver | HCC | exit from host | 28/7958 | 34/18723 | 2.21e-06 | 2.99e-05 | 28 |
| GO:003589111 | Liver | HCC | exit from host cell | 28/7958 | 34/18723 | 2.21e-06 | 2.99e-05 | 28 |
| GO:00985861 | Liver | HCC | cellular response to virus | 57/7958 | 84/18723 | 2.30e-06 | 3.11e-05 | 57 |
| GO:00324814 | Liver | HCC | positive regulation of type I interferon production | 41/7958 | 58/18723 | 1.29e-05 | 1.44e-04 | 41 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM15 | SNV | Missense_Mutation | c.663N>T | p.Lys221Asn | p.K221N | Q9C019 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-B6-A40C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | cyclophosphamide | SD | |
| TRIM15 | SNV | Missense_Mutation | novel | c.641C>T | p.Thr214Ile | p.T214I | Q9C019 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TRIM15 | SNV | Missense_Mutation | c.605N>T | p.Arg202Met | p.R202M | Q9C019 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| TRIM15 | SNV | Missense_Mutation | rs866090988 | c.907N>A | p.Ala303Thr | p.A303T | Q9C019 | protein_coding | deleterious(0.01) | benign(0.412) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TRIM15 | SNV | Missense_Mutation | rs761388796 | c.793N>T | p.Arg265Cys | p.R265C | Q9C019 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM15 | SNV | Missense_Mutation | c.1213N>A | p.Asp405Asn | p.D405N | Q9C019 | protein_coding | tolerated(0.48) | benign(0.34) | TCGA-CM-4752-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TRIM15 | SNV | Missense_Mutation | novel | c.1043N>A | p.Arg348His | p.R348H | Q9C019 | protein_coding | tolerated(0.08) | benign(0.012) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM15 | SNV | Missense_Mutation | novel | c.684N>T | p.Gln228His | p.Q228H | Q9C019 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TRIM15 | SNV | Missense_Mutation | novel | c.757N>T | p.Pro253Ser | p.P253S | Q9C019 | protein_coding | deleterious(0) | possibly_damaging(0.683) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM15 | SNV | Missense_Mutation | rs773260272 | c.338N>T | p.Ala113Val | p.A113V | Q9C019 | protein_coding | tolerated(0.05) | benign(0.095) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |